Potential gains and concerns in nation’s pharma landscape

Potential gains and concerns in nation’s pharma landscape

The pharmaceutical industry is expected to not only continue its vital role in improving health outcomes of all Vietnam citizens driven through innovation.
Imexpharm announces 2025 growth targets

Imexpharm announces 2025 growth targets

Imexpharm has approved its 2025 growth plan, targeting total revenue of VND2.98 trillion
Health Ministry, Sanofi strengthen cooperation in pharmaceutical industry development

Health Ministry, Sanofi strengthen cooperation in pharmaceutical industry development

Sanofi-Aventis Vietnam Co., Ltd. is seeking to strengthen cooperation with the Ministry of Health (MoH) to increase access to new medicines for Vietnamese people and promote the local pharmaceutical industry development.
Green growth paves sustainable path for pharmaceutical industry

Green growth paves sustainable path for pharmaceutical industry

Green growth is becoming essential for pharmaceutical companies in the face of increasingly severe climate change.
Stimulating year ahead for pharma

Stimulating year ahead for pharma

Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.
Promoting pharma technology transfer with more policy support

Promoting pharma technology transfer with more policy support

Experts have urged Vietnam to issue more support policies to facilitate technology transfer in pharmaceuticals and vaccine manufacturing.
Pharma seeks tech transfer incentives

Pharma seeks tech transfer incentives

With growing interest in technology transfer for pharmaceutical and vaccine manufacturing in Vietnam, multinational corporations are urging the government to issue more supporting policies.
The ups and downs of pharma-led tech transfer

The ups and downs of pharma-led tech transfer

With high connectivity and spillover, the pharmaceutical industry can contribute to Vietnam’s becoming a high-income country and one of the top industrialised countries in Asia by 2045.
New legal upgrades can aid pharma tech transfer

New legal upgrades can aid pharma tech transfer

Vietnam’s pharmaceutical industry has made notable achievements in recent times. The total value of the market has increased from $3.4 billion in 2015 to $7.46 billion in 2022, with an annual growth rate of about 12-15 per cent.
Promoting technology transfer for drug and vaccine production in Vietnam

Promoting technology transfer for drug and vaccine production in Vietnam

The Health Strategy and Policy Institute held a conference on December 25 to promote technology transfer for drug and vaccine production in Vietnam.
Vinapharm CEO awarded as Master Entrepreneur 2024

Vinapharm CEO awarded as Master Entrepreneur 2024

On October 3, Han Thi Khanh Vinh, member of the Board of Directors and CEO of Vietnam Pharmaceutical Corporation (Vinapharm), was honoured with a Master Entrepreneur Award at the Asia Pacific Enterprise Awards (APEA) 2024.
Competition within ASEAN for pharma investment

Competition within ASEAN for pharma investment

With an ageing population, rising disease burden, and advancements in healthcare science, the global pharmaceutical market has seen significant growth in recent years. In 2023, the total market was estimated at $1.6 trillion, an increase in over $100 billion compared to 2022. As one of the largest and fastest-growing industries, the sector drives healthcare innovation globally.
Pharma to experience robust growth

Pharma to experience robust growth

Vietnam healthcare market size is estimated to reach $23.7 billion and grow at an average rate of 7.5 per cent annually from 2023 to 2028. Healthcare expenditure per capita is also projected to increase from $237 to $328 in that time.
Vietnam's pharmaceutical market boasts immense potential

Vietnam's pharmaceutical market boasts immense potential

Vietnam has among the highest pharmaceutical industry growth rates worldwide.
Imexpharm announces interim results for H1

Imexpharm announces interim results for H1

Imexpharm Corporation has announced its interim results for the first six months of 2024.
1 2